Abstract 568P
Background
Testing for DNA mismatch repair deficiency (MMRd) is recommended for all colorectal cancers (CRC). Automation of this would facilitate precision medicine, particularly if it provided information on likely aetiology.
Methods
We developed AIMMer, an AI-based method for determination of MMR protein expression at single cell level from IHC-stained routine pathology samples. We applied it to over 2,000 cases from the SCOT clinical trial, which compared 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy (mFOLFOX6 or CAPOX) for stage II/III CRC. AIMMer performance was evaluated against ground truth established by blinded review by two expert pathologists, and MMRd prognostic and predictive value was determined by Cox proportional hazards models.
Results
Benchmarking of AIMMeR against pathologist ground truth MMR calls revealed AUROC of 0.98 (bootstrap 95% CI = 0.97–0.99) and Youden index (sensitivity plus specificity) of 1.87 at cutpoint of 10.7% MMR positive cells. This cutpoint gave positive predictive value (PPV) of >95% for both the commonest pattern of somatic MMRd (MLH1 and PMS2 loss) and for MMR proficient (MMRp) status, and agreement with pathologist calls approaching that between individual pathologists (k = 0.79–0.82 vs 0.88). Analysis of CRC recurrence-free interval (RFI) confirmed MMRd prognostic value in oxaliplatin-treated patients (multivariable-adjusted HR (aHR) = 0.62, 95% CI = 0.44–0.88, P=0.007), with effect size larger in those <70 years and those with right-sided tumours. MMRd did not predict differential benefit from chemotherapy duration. Patients with MMRp tumors had similar RFI whether treated with CAPOX or FOLFOX (aHR = 0.95, 95% CI= 0.77-1.16, P=0.6), while those with MMRd tumours treated with FOLFOX had shorter RFI (aHR = 2.08, 95% CI= 1.09-3.97, P=0.027, P INTERACTION=0.04).
Conclusions
AIMMeR holds promise to reduce pathologist workflow and streamline clinical diagnostics in CRC. The possible predictive value of MMRd for chemotherapy regimen should be investigated in additional cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D.N. Church.
Funding
Cancer Research UK, National Institute for Health Research (NIHR), Promedica.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592P - The role of early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer
Presenter: Jinjia Chang
Session: Poster session 10
594P - The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st- or 2nd-line chemotherapy
Presenter: Naoki Izawa
Session: Poster session 10
595P - The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Presenter: Jaume Capdevila Castillon
Session: Poster session 10
597P - Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
Presenter: Martin Weiser
Session: Poster session 10
598P - Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Presenter: Flavius Sandra-Petrescu
Session: Poster session 10
599P - R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Presenter: Javier Carrasco
Session: Poster session 10